Research programme: cancer and CNS disorder therapeutics - VECT-HORUS

Drug Profile

Research programme: cancer and CNS disorder therapeutics - VECT-HORUS

Alternative Names: VH-N439

Latest Information Update: 14 Apr 2015

Price : $50

At a glance

  • Originator VECT-HORUS
  • Class Drug conjugates; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain cancer; Cerebral ischaemia; Hypoxia
  • Research Adrenal cancer; Hepatocellular carcinoma; Lysosomal storage diseases; Pancreatic cancer

Most Recent Events

  • 14 Apr 2015 Research programme: cancer and CNS disorder therapeutics - VECT-HORUS is available for licensing as of 14 Apr 2015. http://www.vect-horus.com/#c673
  • 14 Apr 2015 Early research in Adrenal cancer in France (Parenteral)
  • 14 Apr 2015 Early research in Hepatocellular carcinoma in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top